FRI0233 MORTALITY IN SLE PATIENTS COMPARED TO POPULATION CONTROLS IN FINLAND IN YEARS 2000–2015

Background: It is well established from a variety of studies that systemic lupus erythematosus (SLE) patients have a shortened life expectancy. The literature on SLE has highlighted the impact of cardiovascular diseases (CVD) on increased mortality 1,2. However, there is lack of studies comparing results to the background population. Objectives: Aim of the study was to clarify, whether incident SLE patients have an excess mortality compared to population controls. Methods: The study included all adult (age ≥ 17 years), incident SLE patients who were entitled to a special reimbursement for SLE medication in years 2000 – 2014 in Finland. For each patient, the Population Register Centre identified 3 population controls matched for age, sex and place of residence. Comorbidities at baseline were obtained from the Care Register for Health Care of the National Institute for Health and Welfare. Data on education at baseline and deaths until the end of 2015 were retrieved from the Statistics Finland. Results: A total of 1006 incident SLE patients (84% females) and 3005 population controls were found. During the follow-up (mean 8.6 years), 98 patients (mean age at death 70±14 years, 65% females) died. The 5 -, 10-, and 15-year survival rates in SLE patients were 95.0% (95%CI 93.3-96.2%), 88.8% (86.2-91.0%) and 82.1% (77.6-85.8%), respectively. The number of deaths among controls was 187. Crude hazard ratio (HR) was 1.61 (95% CI: 1.26 to 2.06), p Conclusion: SLE patients had a slightly increased risk for overall and cardiovascular related mortality compared to population controls. After adjusting for education and comorbidities, the difference was not statistically significant. References: [1] Bernatsky S, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7. [2] Bjornadal L, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004;31:713-9. Disclosure of Interests: Pia Elfving Speakers bureau: Mylan Finland Oy, Abbvie Oy, UCB Pharma Oy Finland, Hannu Kautiainen: None declared, Lauri Virta: None declared, Oili Kaipiainen-Seppanen Speakers bureau: Boehringer Ingelheim, Kari Puolakka: None declared